For international orders (non-US), use this site. For US orders only, visit archerdx.com

Archer® FusionPlex® Oncology Research Kit

The Archer FusionPlex Oncology Research Kit is a targeted enrichment assay that can be used to create libraries for next generation sequencing. Read More...
Select Product(s)

Archer FusionPlex Oncology Research Kit - 8 reactions

AB0009

Price
 
 
Accessory Products

Archer MBC Adapters A17-A24

SA0042

Price
 
 

Archer MBC Adapters A25-A32

SA0043

Price
 
 

Archer MBC Adapters A33-A40

SA0044

Price
 
 

Archer MBC Adapters A41-A48

SA0045

Price
 
 

Archer SureShot ALK, RET, ROS1 Fusion Controls

AK0035-4

Price
 
 

Archer SureShot Negative Fusion Controls

AK0036-4

Price
 
 

Product Highlights

The Archer FusionPlex Oncology Research Kit is a next generation sequencing (NGS) assay to simultaneously detect and identify fusions and other mutations associated with 75 genes found in RNA transcripts that are linked to various cancers. Archer has developed a comprehensive kit to rapidly detect translocations from total nucleic acid isolated from tumor samples, including FFPE preserved specimens. Anchored Multiplex PCR (AMPTM) enrichment chemistry enables targeted amplification of fusion mRNAs, creating libraries that are optimal for multiplex NGS-based fusion detection. Archer technology permits the simultaneous detection of both known recurrent fusions as well as previously unidentified fusions at key breakpoints in target genes. The Archer FusionPlex Oncology Research Kit offers comprehensive NGS-based fusion detection, from library preparation through data analysis.

  • High throughput - protocol increases ability to systematically detect and discover fusions in tumor samples
  • Expert design - >98% panel uniformity and minimal off targeting due to superlatively optimized primer design
  • Extensive - the most comprehensive FusionPlex kit available

Specifications

Product Literature

Report on FFPE Extraction Methods

White Paper | PDF 2 MB

PreSeq RNA QC Assay

White Paper | PDF < 1 MB

Archer FusionPlex Assay Targets

Brochure | PDF 1 MB

Manuals and Support Information

All Archer FusionPlex Support 

Related Products

References
  1. Cantwell-Dorris et al. BRAFV600E: Implications for Carcinogenesis and Molecular Therapy. MOL Cancer Ther. 10(3):385-94(2011).
  2. Ma et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 63(19):6272-81 (2003).
  3. Ashworth et al. Deletion-based mechanisms of NOTCH1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in NOTCH1. Blood. 116(25):5455-5464 (2010).
  4. Ozawa et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes & Dev. 24: 2205-2218 (2010).
  5. E. Lierman et al., FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia. 23:845-851 (2009).